Trial Details
Not RecruitingBasic Information
| Clinical ID | c5391 |
|---|---|
| Identifier | CTRI/2018/10/015908 |
| Trial Title | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative ColitisLUCENT 1 |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | Health Condition 1: K519- Ulcerative colitis, unspecified |
| Interventions | Intervention1: blinded intravenous administration of300 mg mirikizumab: Patients will be randomized with 3:1 ratio to receive blinded Intravenous AdministrationDuration of treatment with the investigational product is 12 weeks. |
Participant Information
| Sponsor | Eli Lilly and Company Lilly |
|---|---|
| City | NULL |
| Country/Region | Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Ireland;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Republic of Korea;Romania;Russia;Saudi Arabia;Serbia;Slovakia;Spain |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | NULL |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |